

ISG15-CHOP-Reporter Kit

MANUAL

**ISG15-CHOP-Reporter DeISGylation Assay Kit
Catalog Number PR1005**

all products are for research use only • not intended for human or animal diagnostic or therapeutic uses
LifeSensors, Inc., 271 Great Valley Parkway, Malvern PA 19355 • (p) 610.644.8845 (f) 610.644.8616
techsupport@lifesensors.com • www.lifesensors.com • sales@lifesensors.com
Copyright © 2007 LifeSensors, Inc. All Rights Reserved

ISG15-CHOP-Reporter Kit

BACKGROUND

Ubiquitin and Ubiquitin Like Proteins

In cells, proteins are tagged for degradation by ubiquitin and sent to the proteasome. In contrast, covalent modification of cellular proteins by the ubiquitin-like modifier SUMO (small ubiquitin-like modifier) regulates various cellular processes, such as nuclear transport and signal transduction. The ubiquitin family of proteins fall into two classes: the first class, ubiquitin-like proteins (UBLs) function as modifiers in a manner analogous to that of ubiquitin. Examples of UBLs are SUMO, Nedd8 (also called Rub1), ISG15, Apg8, Apg12, and Fat10. Proteins of the second class include parkin, RAD23 and DSK2, are designated ubiquitin-domain proteins (UDPs). These proteins contain domains that are related to ubiquitin but are otherwise unrelated.

Conjugation Machinery

The conjugation of Ub/UBLs to target proteins requires an orchestrated addition of Ub/UBLs to lysine residues in the target protein by E1 (activating enzyme), E2 (conjugating enzyme), and E3 (ligase) in an ATP dependent manner. The enzymes form an isopeptide bond between the carboxy-terminus of the UBL and the ϵ -amino group of the lysine residue of target proteins.

DeISGylating Enzymes

ISGylation is a reversible process in which deconjugation is performed in cells by deISGylating enzymes, otherwise known as isopeptidases. Isopeptidases are cysteine proteases that can be divided into multiple families. The roles of isopeptidases include recycling of fused ubiquitin/UBL and processing pro-ubiquitin/UBL by cleavage to the mature form. Removal of ubiquitin or UBL moieties can affect cellular physiology in a number of ways, and several isopeptidases have been linked to pathologies such as cancer and cardiovascular disease.

ABOUT THE ASSAY

The ISG15-CHOP-Reporter DeISGylation Assay consists of ISG15 fused to a reporter enzyme and the reporter enzyme substrate. Upon conjugation of ISG15, the reporter is rendered catalytically inactive. Following cleavage of the ISG15-reporter system by isopeptidase activity, the activated, free reporter subsequently acts upon its substrate. Thus, in the coupled assay, the signal generated by cleavage of the reporter enzyme's substrate is a quantitative measure of isopeptidase activity.

BENEFITS

1. Rapid and robust readout for deISGylating activity within 60 minutes; signal to background ratio >30.
2. Non-radioactive reporter substrates.
3. Miniaturization to multiwell format; cost effective screening.
4. Assay tests deconjugating activity between ISG15 and a physiologically relevant protein.

ISG15-CHOP-Reporter Kit

SUGGESTED USES

1. Demonstrate novel isopeptidase activity.
2. High throughput screening for inhibitors or activators of isopeptidase activity.

COMPONENTS

1. ISG15-CHOP-Reporter (Reporter System)

Size: 1 x 220 μ l (4 μ M)

Buffer: 20 mM Tris (pH 8.0), 150 mM NaCl, 10% glycerol

Storage: -80° C, avoid cycles of freezing and thawing

2. PLpro (Control Isopeptidase)

Size: 2 x 10 μ l (2 μ M)

Buffer: 20 mM Tris (pH 8.0), 150 mM NaCl, 10% glycerol, 200 μ g/ml BSA

Storage: -80° C, avoid cycles of freezing and thawing

3. Reporter Substrate

Size: 1 x 120 μ l (5 mM)

Buffer: ethanol

Storage: -20° C

Misc.: light sensitive

excitation/emission wavelength maxima are 472/552 nm

ADDITIONAL ITEMS REQUIRED

1. Assay Buffer (For Use In Step 1 of Protocol)

20 mM Tris-HCl (pH 8.0), 2 mM CaCl₂, 2 mM β -mercaptoethanol

Prepare fresh assay buffer on a daily basis

2. Fluorescence Plate Reader

Appropriate filters required for excitation and emission wavelengths

Excitation: 460-475 nm

Emission: 538-555 nm

3. Black 96 Well Plate, or Desired Template

4. 15 ml Falcon Tube

5. 1.5 ml snap cap tubes

SOLUTIONS

PLpro (Control Isopeptidase) (For Use In Step 2 of Protocol)

1. Add 490 μ l of assay buffer to one of the tubes labeled PLpro.
2. Vortex the tube.
3. You are now ready to add 50 μ l aliquots into the wells of a black 96 well plate.
4. Each 50 μ l aliquot contains 40nM PLpro.

Reporter Substrate Solution (For Use In Step 4 of Protocol)

1. Perform this step in a timely manner as to minimize exposure of the reporter substrate to light.
2. Combine 1.6 μ l reporter substrate, and 198.4 μ l of assay buffer in a 1.5 ml snap cap tube.
3. Vortex the tube.
4. You are now ready to add 50 μ l aliquots into the wells of a black 96 well plate.

ISG15-CHOP-Reporter (Reporter System) and Reporter Substrate Solution (For Use In Step 5 of Protocol)

1. Perform this step in a timely manner as to minimize exposure of the reporter substrate to light.
2. Combine 90 μ l of ISG15-CHOP-Reporter, 48 μ l reporter substrate, and 5.86 ml of assay buffer in a 15 ml Falcon Tube.
3. Vortex the tube, you are now ready to add 50 μ l aliquots into the wells of a black 96 well plate
4. Immediately add a 50 μ l aliquot of 60nM ISG15-CHOP-Reporter and 40 μ M reporter substrate to 50 μ l of isopeptidase.

Test Isopeptidase (For Use In Step 3 of Protocol)

We suggest an initial dilution series of your test isopeptidase to optimize its concentration/activity. As a positive control, the kit includes the catalytic core domain of the enzyme PLpro, to be used at a concentration of 20nM in the final reaction. Make the dilutions of your test isopeptidase in assay buffer such that a final volume of 50 μ l is added to each well. A suggested protocol is listed below.

1. Label seven 1.5 ml snap cap tubes T1 through T7.
2. Place 200 μ l of assay buffer in tubes T2 through T7.
3. Dilute the test isopeptidase to a concentration of 800nM in 400 μ l of Assay Buffer in Tube T1.
4. Vortex Tube T1 and perform a 2-fold dilution by transferring 200 μ l of solution from Tube T1 into Tube T2.
5. Perform another 2 fold dilution by taking 200 μ l from Tube T2 and placing it into Tube T3.
6. Repeat for Tubes T4 through T7.

ISG15-CHOP-Reporter Kit

tube	Concentration of test isopeptidase in 50 μ l (nM)	Concentration of test isopeptidase in 100 μ l (nM)
T1	800	400
T2	400	200
T3	200	100
T4	100	50
T5	50	25
T6	25	12.5
T7	12.5	6.25

PROTOCOL

Optimization of Your Test Isopeptidase, Suggested Protocol

1. Add 50 μ l of Assay Buffer in triplicate to columns 1 and 2.
2. Add 50 μ l of PLpro (control isopeptidase) in triplicate to column 3.
3. Add 50 μ l of Tubes T1-T7 of your test isopeptidase in triplicate to columns 4 through 10.
4. Add 50 μ l of reporter substrate solution in triplicate to column 1.
5. Add 50 μ l of reporter and reporter substrate solution in triplicate to columns 2 through 10.
6. Below gives a representation of the 96 well plate layout.

	1	2	3	4	5	6	7	8	9	10	11	12
A	50 μ l Assay Buffer + 50 μ l Reporter Substrate	50 μ l Assay Buffer + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l PLpro + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T1 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T2 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T3 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T4 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T5 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T6 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T7 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate		
B	50 μ l Assay Buffer + 50 μ l Reporter Substrate	50 μ l Assay Buffer + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l PLpro + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T1 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T2 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T3 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T4 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T5 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T6 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T7 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate		
C	50 μ l Assay Buffer + 50 μ l Reporter Substrate	50 μ l Assay Buffer + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l PLpro + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T1 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T2 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T3 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T4 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T5 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T6 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate	50 μ l Tube T7 + 50 μ l ISG15-CHOP-Reporter & Reporter Substrate		
D												
E												
F												
G												
H												

7. Incubate for 30-60 minutes and detect fluorescence. There are two options for fluorescence detection. First, the plate can be incubated at room temperature for 30-60 minutes, in the dark, and a single time point reading can be measured using the appropriate excitation and emission

ISG15-CHOP-Reporter Kit

filters, 460-475 and 538-555 nm, respectively. Alternatively, an in-plate kinetic reading can be performed by measuring the change in fluorescence over time.


8. Determine the mean plate blank value (column 1 in the representative example) and subtract from each data point to give a true representation of the change in fluorescence intensity. It is recommended that each experimental condition is measured in triplicate.

QUALITY CONTROL

Quality Control

In a 96 well plate, 30nM ISG15-CHOP-Reporter and 20 μ M reporter substrate were incubated in the presence and absence of 20nM PLpro. Liberation of the fluorescent reporter substrate was monitored on a fluorescence plate reader using an excitation wavelength of 460 nm and an emission wavelength of 538 nm. Net RFU was determined by subtracting the blank (reporter substrate alone) from each data point. Results are shown in the figure below.

Representative experiment. Data = mean \pm standard deviation



REFERENCES

- Nicholson, B, Leach, C.A., et al (2008). "Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities." *Prot. Sci.*, in press
- Arnold, J.J., Bernal, A., et al. (2005). "Small ubiquitin-like modifying protein isopeptidase assay based on poliovirus RNA polymerase activity." *Anal Biochem*, Nov 17.
- Hall, J., Mattern, M., and Butt, T. (2005). "Mining the ubiquitin pathway." *The Scientist* 19 (23): 42-43.
- Lindner, H. A., Fotouhi-Ardakani, N. et al. (2005). "The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme." *J Virol* 79(24): 15199-15208
- Ciechanover, A. (2003) "The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting." *Biochem Soc Trans* 31(2): 474-81.
- Hochstrasser, M. (2002). "Molecular biology. New proteases in a ubiquitin stew." *Science* 298(5593): 549-52.
- Ciechanover, A. (2001). "Ubiquitin-mediated degradation of cellular proteins: why destruction is essential for construction, and how it got from the test tube to the patient's bed." *Isr Med Assoc J* 3(5): 319-27.
- Wilkinson, K. D. (2000). "Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome." *Semin Cell Dev Biol* 11(3): 141-8.
- Chung, C. H. and S. H. Baek (1999). "Deubiquitinating enzymes: their diversity and emerging roles." *Biochem Biophys Res Commun* 266(3): 633-40.

ISG15-CHOP-Reporter Kit

Dang, L. C., F. D. Melandri, et al. (1998). "Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes." *Biochemistry* 37(7): 1868-79.

Hershko, A. and A. Ciechanover (1998). "The ubiquitin system." *Annu Rev Biochem* 67: 425-79.

Wilkinson, K. D. (1997). "Regulation of ubiquitin-dependent processes by deubiquitinating enzymes." *Faseb J* 11(14): 1245-56.

Hochstrasser, M. (1996). "Ubiquitin-dependent protein degradation." *Annu Rev Genet* 30: 405-39.

LIMITED USE LABEL LICENSE

CHOP-Reporter Technology is licensed from Progenra, Inc. For information on obtaining a license for commercial purposes, contact: Michael Mattern, Ph.D., Vice President Research, Progenra, Inc., Malvern PA 19355, Phone: 610.644.6974 ext 319.

The product and/or its derivatives are being furnished to the purchaser under the following conditions: By purchasing the product, the purchaser agrees to comply with the terms of this Limited Use Label License. The product is provided to purchaser for research use only. The purchaser of this product may not transfer or otherwise sell this product or its derivatives to a third party and no rights are given to the purchaser to use the product or its derivatives for commercial purposes as defined below.

Commercial purposes means any activity for which a party receives consideration and may include, but is not limited to,

1. use of the product or its derivatives in manufacturing,
2. use of the product or its derivatives to provide a service, information, or data,
3. use of the product or its derivatives for diagnostic purposes,
4. transfer or sell of protein or chemical component made with the product or derivatives of the product,
5. resell the product or its derivatives, whether or not such product or its derivatives are resold for use in research.

Product use must follow compliance with all laws and regulations, including but not limited to current EPA, FDA, USDA, and NIH guidelines. THE MATERIALS WILL NOT BE USED IN HUMANS.

Purchaser acknowledges that the product is experimental in nature and provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. LIFESENSORS, INC. MAKES NO REPRESENTATION OR WARRANTY THAT THE USE OF THE PRODUCT WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS.

In no event shall LifeSensors, Inc. be liable for any use of the product by purchaser. Purchaser agrees to defend, indemnify, and hold harmless LifeSensors, Inc. its officers, employees, and agents from any loss, claim, injury, damage, expense, or liability (including attorney's fees), of whatsoever kind or nature, which may arise from or in connection with this Agreement, including but not limited to purchaser use, handling or storage of the product.